BioXcel Therapeutics announced a key executive promotion and a clinical advisor appointment as part of the Company’s strategic reprioritization focused on the advancement of its late-stage clinical programs and emerging pipeline candidates. Vincent J. O’Neill, M.D., Senior Vice President and Chief Research & Development Officer of OnkosXcel Therapeutics, has been promoted to Executive Vice President, Chief of Product Development and Medical Officer of BioXcel Therapeutics. He will lead clinical, regulatory and medical affairs to provide a fully integrated approach to product development. Additionally, Rajiv Patni, M.D., has been appointed to the newly created position of Strategic Clinical Advisor to the BioXcel Therapeutics Chief Executive Officer and Board of Directors. Patni was Chief Research and Development Officer at Reata Pharmaceuticals,
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BTAI:
- BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
- Largest borrow rate increases among liquid names
- BioXcel raises ‘substantial doubt’ about continuing as going concern
- BioXcel Therapeutics rating suspended at Goldman Sachs
- BioXcel Therapeutics price target lowered to $18 from $20 at Canaccord
Questions or Comments about the article? Write to editor@tipranks.com